Long-term ALS survival benefit with CNM-Au8 seen in trial analyses

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia - ScienceDirect

CNM-Au8 for amyotrophic lateral sclerosis

Ublituximab Outperforms Teriflunomide on ARRs, CNM-Au8 Fails HEALEY ALS Trial, Benefits of Aerobic Exercise in Multiple Sclerosis

Kaplan–Meier survival curves from masitinib study AB10015 long-term

Long-term ALS survival benefit with CNM-Au8 seen in trial analyses, HEALEY ALS trial now tested therapy for up to 2.5 years in patients

Clene Nanomedicine, Inc. on LinkedIn: #als #cnmau8 #gold #nanocrystal #neurodegeneration

Trial Results from Clene Nanomedicine Strike ALS Research

Clene's phase II gold nanocrystal data mined; prospects good ore bad in ALS?, 2021-11-02

Synapticure on Science: Clinical Trials for Sporadic ALS

Clene: Still in the Running for ALS

Frontiers New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022

Latest ALS Clinical Trial Information – We provide up-to-date, scientific ALS clinical trial information

cdn.sanity.io/images/0vv8moc6/neurolive/6a4093ab3e